Please assess the completion status of the following clinical trial:

Trial Title: Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Note: As of 08/10/07, the arm assignments for current and new participants have changed. Please see the above description for this trial for more information.~Inclusion Criteria for Mothers:~* 18 years of age or older~* HIV infected~* In third trimester of pregnancy, or at most 3 days post-delivery~* If baby is not yet born, planning to deliver at a facility where the study is being conducted~* Plan to breastfeed~Exclusion Criteria for Mothers:~* Complications with this pregnancy~* Serious medical condition that would interfere with the study (e.g., that would prevent breastfeeding or adherence to the follow-up schedule), as judged by the on-site clinician~Inclusion Criteria for Infants:~* Born to an HIV infected mother who is eligible for the study~* Weighed at least 2000 grams (4.4 lbs) at birth~* Blood sample obtained from the infant for HIV-1 DNA PCR, CBC with differential, and ALT~* Infants in a multiple birth are eligible only if both/all infants are eligible for the study and assigned to the same study group~* Able to breastfeed (e.g., mother and infant alive with no condition apparent that would prevent breastfeeding)~Exclusion Criteria for Infants:~* HIV DNA PCR positive at birth~* ALT of Grade 2 or higher at birth~* Hemoglobin, absolute neutrophil count, or platelet count of Grade 3 or higher at birth~* Skin rash of Grade 2B (urticaria), Grade 3, or above~* Confirmed or suspected clinical hepatitis~* Serious illness or condition that would interfere with compliance with study procedures

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2A (Type: EXPERIMENTAL): For infants: extended treatment with NVP
- 2B (Type: PLACEBO_COMPARATOR): For infants: extended treatment with NVP placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).